Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.40114 http://scihub22266oqcxt.onion/10.1002/art.40114 C5560126!5560126!28376288     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arthritis+Rheumatol 2017 ; 69 (7): 1451-60 Nephropedia Template TP {{tp|p=28376288|t=2017. Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II |pdf=|usr=}}{{28376288}} gab.com Text Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=28376288 #FOAvip Objective: To compare mycophenolate (MMF) with placebo for the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD). Methods: Participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II were included. SLS I randomized participants to oral cyclophosphamide (CYC) versus placebo for 1 year, while SLS II randomized participants to MMF for 2 years versus oral CYC for 1 year followed by 1 year of placebo. Eligibility criteria for SLS I and II were nearly identical. The primary outcome was FVC%-predicted and key secondary outcomes included the DLCO%-predicted, skin score, and dyspnea. Joint models were created to evaluate the treatment effect on the course of these outcomes over 2 years. Results: SLS II-MMF (N=61) and SLS I-placebo (N=61) participants had similar baseline characteristics for gender, disease duration, SSc subtype, extent of skin disease and FVC%-predicted. SLS II-MMF patients were slightly older (mean[SD] years: 52.6[9.7] vs. 48.1[12.4]; P=0.015) and had a higher DLCO%-predicted (mean[SD]: 54.0[11.1] vs. 46.2[13.3]; P=0.0002) than SLS I-placebo participants. After adjusting for baseline disease severity, treatment with MMF in comparison with placebo was associated with an improved course of FVC%-predicted (P<0.0001), DLCO%-predicted (P<0.001), skin score (P<0.0001), and dyspnea (P=0.0112) over 2 years. Conclusions: Although there are inherent limitations in comparing participants from different trials, treatment with MMF was associated with improvements in physiologic outcomes and dyspnea compared with placebo, even after accounting for baseline disease severity. These results further substantiate the use of MMF for the treatment of SSc-ILD. Twit Text FOAVip Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=28376288 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28376288 #FOAvip English Wikipedia <ref>{{Cite pmid|28376288}}</ref> Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II #MMPMID28376288 Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM Arthritis Rheumatol 2017[Jul]; 69 (7): 1451-60 PMID28376288show ga Objective: To compare mycophenolate (MMF) with placebo for the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD). Methods: Participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II were included. SLS I randomized participants to oral cyclophosphamide (CYC) versus placebo for 1 year, while SLS II randomized participants to MMF for 2 years versus oral CYC for 1 year followed by 1 year of placebo. Eligibility criteria for SLS I and II were nearly identical. The primary outcome was FVC%-predicted and key secondary outcomes included the DLCO%-predicted, skin score, and dyspnea. Joint models were created to evaluate the treatment effect on the course of these outcomes over 2 years. Results: SLS II-MMF (N=61) and SLS I-placebo (N=61) participants had similar baseline characteristics for gender, disease duration, SSc subtype, extent of skin disease and FVC%-predicted. SLS II-MMF patients were slightly older (mean[SD] years: 52.6[9.7] vs. 48.1[12.4]; P=0.015) and had a higher DLCO%-predicted (mean[SD]: 54.0[11.1] vs. 46.2[13.3]; P=0.0002) than SLS I-placebo participants. After adjusting for baseline disease severity, treatment with MMF in comparison with placebo was associated with an improved course of FVC%-predicted (P<0.0001), DLCO%-predicted (P<0.001), skin score (P<0.0001), and dyspnea (P=0.0112) over 2 years. Conclusions: Although there are inherent limitations in comparing participants from different trials, treatment with MMF was associated with improvements in physiologic outcomes and dyspnea compared with placebo, even after accounting for baseline disease severity. These results further substantiate the use of MMF for the treatment of SSc-ILD. äMycophenolate versus Placebo for Systemic Sclerosis-Related Interstiti(epmc).pdf DeepDyve Pubget Overpricing